News summarySynced (Jiqizhixin)Nov 17, 2026, 04:02 AM
Tushen Zhihé Completes Two Pre-A Funding Rounds
aiartificial_intelligencecapital_raisingpharmaceuticals
Founded in 2023, Tushen Zhihé focuses on AI protein design. [[fact-xu0yoyrbu]] The company completed consecutive Pre-A and Pre-A+ rounds totaling several hundred million yuan. [[fact-tnt3p2fww]] The company says its ToursynClaw platform connects design, experiments, feedback, and redesign in a full wet-lab and computational loop. [[fact-6zfzkd12y]] It says it has completed real experimental validation in more than 100 antibody-engineering projects. [[fact-jjkkw1b52]] The company also says it can complete one wet-lab and computational validation cycle in 14 days. [[fact-cknh14979]]